Medpace (NASDAQ:MEDP) Posts Earnings Results

by · The Markets Daily

Medpace (NASDAQ:MEDP – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27, FiscalAI reports. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business had revenue of $707.33 million during the quarter, compared to analysts’ expectations of $689.53 million. Medpace updated its FY 2026 guidance to 17.250-17.950 EPS.

Medpace Trading Down 0.9%

Shares of NASDAQ MEDP traded down $5.04 during trading on Wednesday, reaching $526.63. 507,892 shares of the company traded hands, compared to its average volume of 352,189. The stock has a market cap of $15.04 billion, a P/E ratio of 33.10, a PEG ratio of 2.64 and a beta of 1.15. The firm’s fifty day simple moving average is $482.55 and its 200 day simple moving average is $493.73. Medpace has a 12-month low of $373.00 and a 12-month high of $628.92.

Insider Activity at Medpace

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the sale, the general counsel directly owned 20,343 shares of the company’s stock, valued at $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 20.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Sivia Capital Partners LLC acquired a new position in shares of Medpace in the 2nd quarter valued at $296,000. Moneta Group Investment Advisors LLC acquired a new stake in Medpace during the third quarter valued at $209,000. Northwestern Mutual Wealth Management Co. grew its position in Medpace by 16.0% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 405 shares of the company’s stock valued at $208,000 after buying an additional 56 shares during the period. Olympiad Research LP purchased a new position in Medpace in the fourth quarter valued at $203,000. Finally, Abel Hall LLC acquired a new position in shares of Medpace in the fourth quarter worth about $202,000. 77.98% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently issued reports on MEDP. Royal Bank Of Canada cut their target price on Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Robert W. Baird reiterated a “neutral” rating and set a $547.00 price target (up from $477.00) on shares of Medpace in a research note on Wednesday, July 8th. Mizuho increased their price objective on Medpace from $495.00 to $586.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Finally, Barclays reduced their price objective on Medpace from $500.00 to $450.00 and set an “equal weight” rating for the company in a research note on Friday, April 24th. Two analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Medpace has a consensus rating of “Hold” and an average target price of $469.50.

View Our Latest Research Report on Medpace

Medpace Company Profile

(Get Free Report)

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.

Read More